1. Home
  2. TONT vs TNYA Comparison

TONT vs TNYA Comparison

Compare TONT & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TONT

Graf Global Corp. Class A ordinary shares

SELL

Current Price

$10.98

Market Cap

154.5M

Sector

N/A

ML Signal

SELL

Logo Tenaya Therapeutics Inc.

TNYA

Tenaya Therapeutics Inc.

N/A

Current Price

$0.30

Market Cap

153.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TONT
TNYA
Founded
2021
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.5M
153.2M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
TONT
TNYA
Price
$10.98
$0.30
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $3.67
AVG Volume (30 Days)
145.6K
★ 2.3M
Earning Date
11-20-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.96
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.81
$0.30
52 Week High
$11.17
$1.46

Technical Indicators

Market Signals
Indicator
TONT
TNYA
Relative Strength Index (RSI) 53.08 27.93
Support Level N/A N/A
Resistance Level N/A $0.42
Average True Range (ATR) 0.02 0.03
MACD 0.00 0.00
Stochastic Oscillator 15.22 6.46

Price Performance

Historical Comparison
TONT
TNYA

About TONT Graf Global Corp. Class A ordinary shares

Graf Global Corp is a blank check company.

About TNYA Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

Share on Social Networks: